Chimeric antigen receptor T cell (CAR T) treatment efficacy has been shown to be greater in those who receive timely infusions, while mortality rates increase with each month's delay in treatment. Yet health care infrastructure constraints, an intricate treat... ...

请注册登录后继续浏览